Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Lymphoma Clinical Trial

Official title: Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Status Recruiting

Clinical Trial Summary

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. Record patients' cognitive outcomes after whole-brain radiation therapy (WBRT) for hematologic malignancies using standard-of-care neurocognitive function testing.

SECONDARY OBJECTIVES:

I. Assess patients' quality-of-life after WBRT for hematologic malignancies, based on a validated questionnaire.

II. Explore magnetic resonance imaging (MRI) changes in the brain after WBRT for hematologic malignancies, based on standard-of-care imaging studies.

III. Study the role of Memantine in patients' cognitive outcomes during and after WBRT for hematologic malignancies, based on standard-of-care use, utilizing standard-of-care neurocognitive function testing.

OUTLINE:

Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years. ;

Related Conditions & MeSH terms

• Central Nervous System Lymphoma
• Hematologic Neoplasms
• Hematopoietic and Lymphoid Cell Neoplasm
• Leukemia
• Lymphoma
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Plasma Cell Myeloma
• Secondary Central Nervous System Lymphoma

• NCT number: NCT05011045
• Study type: Observational
• Source: M.D. Anderson Cancer Center
• Status: Recruiting
• Start date: January 9, 2020
• Completion date: October 31, 2026